Acute GVHD in patients receiving 131I-BC8/FLU/TBI and HLA-matched related and unrelated allogeneic transplants for advanced AML and high-risk MDS
| . | AML (n = 28) . | Secondary AML (n = 19) . | MDS* (n = 11) . | All patients (n = 58) . | |
|---|---|---|---|---|---|
| REM . | REF/REL . | ||||
| Acute GVHD overall grade | |||||
| Grade II | 4 (14) | 12 (43) | 12 (63) | 5 (45) | 33 (57) |
| Grade III | 5 (18) | 0 (0) | 4 (21) | 1 (9) | 10 (17) |
| Grade IV | 0 (0) | 0 (0) | 0 (0) | 1 (9) | 1 (2) |
| Acute GVHD, gut | |||||
| Grade II | 1 (4) | 1 (7) | 3 (16) | 1 (9) | 6 (10) |
| Grade III | 5 (18) | 6 (40) | 5 (26) | 5 (45) | 21 (36) |
| Grade IV | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0) |
| Acute GVHD, skin | |||||
| Grade II | 1 (4) | 0 (0) | 1 (5) | 0 (0) | 2 (4) |
| Grade III | 1 (4) | 0 (0) | 1 (5) | 1 (9) | 3 (5) |
| Grade IV | 0 (0) | 0 (0) | 0 (0) | 1 (9) | 1 (2) |
| Acute GVHD, liver | |||||
| Grade II | 0 (0) | 0 (0) | 2 (11) | 1 (9) | 3 (5) |
| Grade III | 1 (4) | 0 (0) | 1 (5) | 1 (9) | 3 (5) |
| Grade IV | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| . | AML (n = 28) . | Secondary AML (n = 19) . | MDS* (n = 11) . | All patients (n = 58) . | |
|---|---|---|---|---|---|
| REM . | REF/REL . | ||||
| Acute GVHD overall grade | |||||
| Grade II | 4 (14) | 12 (43) | 12 (63) | 5 (45) | 33 (57) |
| Grade III | 5 (18) | 0 (0) | 4 (21) | 1 (9) | 10 (17) |
| Grade IV | 0 (0) | 0 (0) | 0 (0) | 1 (9) | 1 (2) |
| Acute GVHD, gut | |||||
| Grade II | 1 (4) | 1 (7) | 3 (16) | 1 (9) | 6 (10) |
| Grade III | 5 (18) | 6 (40) | 5 (26) | 5 (45) | 21 (36) |
| Grade IV | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0) |
| Acute GVHD, skin | |||||
| Grade II | 1 (4) | 0 (0) | 1 (5) | 0 (0) | 2 (4) |
| Grade III | 1 (4) | 0 (0) | 1 (5) | 1 (9) | 3 (5) |
| Grade IV | 0 (0) | 0 (0) | 0 (0) | 1 (9) | 1 (2) |
| Acute GVHD, liver | |||||
| Grade II | 0 (0) | 0 (0) | 2 (11) | 1 (9) | 3 (5) |
| Grade III | 1 (4) | 0 (0) | 1 (5) | 1 (9) | 3 (5) |
| Grade IV | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Values are n (%).
REM indicates remission; REF/REL, refractory/relapsed.
MDS includes refractory anemia with excess of blasts and chronic myelomonocytic leukemia.